Actuate Therapeutics, Inc. (ACTU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.37+5.69%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ACTU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ACTU — legal / regulatory event — Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard;…
Dated 2026-10-30
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. On October 28, 2026, Actuate Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global…
Why it matters: The study aims to test whether the tablet gives patients more drug exposure than IV treatment. A higher level would support the reason for moving to tablets.
Supportive ifStudy data show higher drug exposure with oral elraglusib than with the IV form.
Worry ifStudy data show oral drug exposure is no higher than with the IV form, or the company reports that the goal was not met.
Why it matters: Nasdaq said the share price stayed below its $1.00 minimum for 30 business days. The company needs to regain compliance to keep its listing.
Worry ifNasdaq confirms the stock closed at or above $1.00 for at least 10 straight business days before the compliance period ends.
Less concerning ifThe company reports it did not meet Nasdaq's deadline to regain compliance, or that Nasdaq starts delisting steps.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$706 on $10,000 · ±7.1% | How much price usually moves either way. |
| Bad day | $1,131 loss on $10,000 · 11.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,561 loss on $10,000 · 95.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.